MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596206 | Name: Iron sorbitex

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Iron Sorbitex is indicated for the treatment of Iron Sorbitex deficiency anemia in patients with chronic kidney disease. Iron Sorbitex is an Iron Sorbitex replacement product indicated for the treatment of Iron Sorbitex deficiency anemia in patients with chronic kidney disease.

Chemical Structure

Iron sorbitex
Iron sorbitex
CAS#62765-90-6

Theoretical Analysis

MedKoo Cat#: 596206

Name: Iron sorbitex

CAS#: 62765-90-6

Chemical Formula: C12H19FeO13

Exact Mass: 427.0175

Molecular Weight: 427.11

Elemental Analysis: C, 33.75; H, 4.48; Fe, 13.07; O, 48.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Iron sorbitex; HSDB 1967; Astra 1572; Yectofer; Jectofer; Iron Sorbitol;
IUPAC/Chemical Name
Iron-sorbitol
InChi Key
WNDUPUMWHYAJOR-SADXPQEKSA-K
InChi Code
InChI=1S/C6H8O7.C6H14O6.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;7-1-3(9)5(11)6(12)4(10)2-8;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);3-12H,1-2H2;/q;;+3/p-3/t;3-,4+,5-,6-;/m.1./s1
SMILES Code
O=C([O-])CC(C([O-])=O)(O)CC([O-])=O.OC[C@](O)([H])[C@](O)([H])[C@@](O)([H])[C@](O)([H])CO.[Fe+3]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 427.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Urbach A, Brueckner J, Witte OW. Cortical spreading depolarization stimulates gliogenesis in the rat entorhinal cortex. J Cereb Blood Flow Metab. 2015 Mar 31;35(4):576-82. doi: 10.1038/jcbfm.2014.232. PubMed PMID: 25515215; PubMed Central PMCID: PMC4420877. 2: Afzal M, Qureshi SM, Lutafullah M, Iqbal M, Sultan M, Khan SA. Comparative study of efficacy, tolerability and compliance of oral iron preparations (iron edetae, iron polymatose complex) and intramuscular iron sorbitol in iron deficiency anaemia in children. J Pak Med Assoc. 2009 Nov;59(11):764-8. PubMed PMID: 20361676. 3: Galleano M, Lemberg A, Puntarulo S. Does hepatomegaly alter iron-dependent oxidative effects in human plasma? Hum Exp Toxicol. 2003 Jul;22(7):401-5. PubMed PMID: 12929730. 4: Poljak-Blazi M, Kralj M, Hadzija MP, Zarković N, Zarković K, Waeg G. Involvement of lipid peroxidation, oncogene expression and induction of apoptosis in the antitumorous activity of ferric-sorbitol-citrate. Cancer Biother Radiopharm. 2000 Jun;15(3):285-93. PubMed PMID: 10941536. 5: Poljak-Blazi M, Zarkovic N, Schaur RJ. Impaired proliferation and DNA synthesis of a human tumor cell line (HeLa) caused by short treatment with the anti-anemic drug jectofer (ferric-sorbitol-citrate) and the lipid peroxidation product 4-hydroxynonenal. Cancer Biother Radiopharm. 1998 Oct;13(5):395-401. PubMed PMID: 10851431. 6: Gupta R, Gupta S, Joshi K, Ganguly NK. Role of iron and iron chelation therapy in oxygen free radical mediated tissue injury in an ascending mouse model of chronic pyelonephritis. Comp Immunol Microbiol Infect Dis. 1997 Sep;20(4):299-307. PubMed PMID: 9481514. 7: Sunder-Plassmann G, Hörl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf. 1997 Oct;17(4):241-50. Review. PubMed PMID: 9352960. 8: Bechensteen AG, Halvorsen S, Skottner A. Recombinant human insulin-like growth factor 1 (rh-IGF-1) stimulates erythropoiesis in adult, but not in newborn mice. Acta Physiol Scand. 1994 May;151(1):117-23. PubMed PMID: 8048331. 9: Voest EE, Neijt JP, Keunen JE, Dekker AW, van Asbeck BS, Nortier JW, Ros FE, Marx JJ. Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother Pharmacol. 1993;31(5):357-62. PubMed PMID: 8431969. 10: Dabbagh AJ, Blake DR, Morris CJ. Effect of iron complexes on adjuvant arthritis in rats. Ann Rheum Dis. 1992 Apr;51(4):516-21. PubMed PMID: 1586252; PubMed Central PMCID: PMC1004704. 11: Raica M. Calciphylaxis induced by iron-citrate sorbitol. Exp Pathol. 1990;38(3):196-200. PubMed PMID: 2358062. 12: Wei SL, Li ZJ, He YK, Huang H, Chen ZS. [Studies on the physical properties of iron sorbitol]. Yao Xue Xue Bao. 1984 Oct;19(10):785-9. Chinese. PubMed PMID: 6544031. 13: Bernát SI, Soós G. [A new method for the determination of iron concentration in urine and its use in intramuscular iron load for the reliable and early detection of iron deficiency conditions]. Folia Haematol Int Mag Klin Morphol Blutforsch. 1983;110(3):437-46. German. PubMed PMID: 6194078. 14: Callender ST. Treatment of iron deficiency. Clin Haematol. 1982 Jun;11(2):327-38. Review. PubMed PMID: 7042154. 15: Guze LB, Guze PA, Kalmanson GM, Glassock RJ. Effect of iron on acute pyelonephritis and later chronic changes. Kidney Int. 1982 Jun;21(6):808-12. PubMed PMID: 6752529. 16: Winter R, Seidel A. The influence of an iron-sorbitol-citrate complex on the deposition of monomeric 239Pu in four rodent species. Health Phys. 1981 Jan;40(1):100-4. PubMed PMID: 7216769. 17: Lindvall S, Rydén L, Smedgärd P, Swedberg B. Alpha-tocopherol and cardiac toxicity of iron. Scand J Haematol. 1980 Oct;25(4):331-8. PubMed PMID: 7209402. 18: Smith FW, Dendy PP, Pocklington T, Dawson AA, Foster MA, Mallard JR. A preliminary investigation of 67Ga citrate distribution in hyperferraemic patients. Eur J Nucl Med. 1980 Aug;5(4):327-32. PubMed PMID: 7398669. 19: Scott DE, Saltin AS, Pritchard JA. Iron sorbitex for treating iron-deficiency anemia. Obstet Gynecol. 1967 Nov;30(5):679-82. PubMed PMID: 6053103. 20: Evaluation of an iron preparation for intramuscular use. Iron sorbitex (jectofer). JAMA. 1966 Jul 11;197(2):135-6. PubMed PMID: 5952496.

View History

Indobufen sodium

Indobufen sodium